Roundhill Russell 2000 0DTE Covered Call Strat ETF vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $26.08 (market cap $159.33M), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.66 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 368.7× Roundhill Russell 2000 0DTE Covered Call Strat ETF's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Roundhill Russell 2000 0DTE Covered Call Strat ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Russell 2000 0DTE Covered Call Strat ETF for 53 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| RDTE | TAK | |
|---|---|---|
Market Cap | $159.33M | $58.74B |
Volume | 248,058 | 3,110,994 |
Sector | Income / Options Overlay | Health |
52-Week High | $33.66 | $19.05 |
52-Week Low | $25.96 | $13.23 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | — | $86.65B |
Dividend Yield | — | 3.33% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →